GlassScriptPhysician profile
Alan N Lieberman
NPI 1881799203
$3,024.61
in general payments reported to CMS, 2019-2025
25 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $297 · 2021: $446 · 2022: $418 · 2023: $465 · 2024: $489 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $549.76 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $379.67 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $351.17 | 2020-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $305.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.85 | 2021-2025 | Jardiance |
| Pfizer INC. | $224.54 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $169.96 | 2021-2025 | |
| Abbott Laboratories | $150.73 | 2019-2020 | |
| Conmed Corporation | $119.98 | 2025 | Airseal |
| Kowa Pharmaceuticals America, INC. | $84.99 | 2020-2021 | |
| Cvrx, INC. | $59.21 | 2023-2024 | Barostim Neo System |
| Boston Scientific Corporation | $50.17 | 2022-2024 | Watchman Flx |
| Agepha Pharma Fz LLC | $43.68 | 2024-2025 | Lodoco |
| Viatris Specialty LLC | $34.92 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $28.48 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $28.00 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $27.82 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $24.01 | 2023 | Inpefa |
| Cleerly, INC. | $21.99 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals International, Plc | $20.10 | 2024 | Arcalyst |
| Amryt Pharma Holdings LTD | $18.34 | 2021 | |
| Merck Sharp & Dohme LLC | $15.85 | 2023 | Verquvo |
| Scpharmaceuticals INC. | $15.84 | 2023 | |
| Esperion Therapeutics, INC. | $15.80 | 2024 | Nexletol |
| Amgen INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.